Industry News

Search Articles:

BioTime submits CE Mark application for European approval of Reneviaź
BioTime announced submission of a design dossier application for CE Mark approval to market Reneviaź in Europe. BioTime anticipates CE Mark approval in the second half of 2018. All Reneviaź transplants were shown to be generally well tolerated and there were no device-related serious adverse events.March 13, 2018